Randomised controlled trial of clozapine in resistant schizophrenia and schizoaffective disorder.

ABSTRACT:

Background

Clozapine (CLZ) stands out for its unique receptor profile, making it more effective than other antipsychotics, especially in treatment-resistant schizophrenia (TRS). There is growing evidence supporting its use in schizoaffective disorder (SZD), although diagnostic challenges and drug characteristics have complicated the implementation of specific clinical trials.

Aim

Compare efficacy and tolerability of CLZ in real-world patients with TRS and SZD.

Methods

Prospective, pragmatic, three-month, evaluator-blinded clinical trial with two randomised controlled arms (TRS groups) and a third fixed arm (SZD group). The clinical response was assessed by monthly visits during which the Positive and Negative Syndrome Scale (PANSS), Young Mania Rating Scale (YMRS), Mo

SUBMITTER: Peraire M 

PROVIDER: S-EPMC12618736 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature